Isabel Weinhäuser

Isabel Weinhäuser

Auto-generated profile, based on publicly available information

Isabel Weinhäuser

Department of Hematology, Cancer Research Centre Groningen, University Medical Centre Groningen, University of Groningen, Groningen, The Netherlands

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
ZSZuzanna Sas
Zuzanna Sas
ECEwa Cendrowicz
Ewa Cendrowicz
IWIsabel Weinhäuser
Isabel Weinhäuser
TRTomasz Rygiel
Tomasz Rygiel
The prevalence of liver cancer is constantly rising, with increasing incidence and mortality in Europe and the USA in recent decades. Among the different subtypes of liver cancers, hepatocellular carcinoma (HCC) is the most commonly diagnosed liver cancer. Besides advances in diagnosis and promising results of pre-clinical studies, HCC remains a highly lethal disease. In many cases, HCC is an effect of chronic liver inflammation, which leads to the formation of a complex tumor microenvironment (TME) composed of immune and stromal cells. The TME of HCC patients is a challenge for therapies, as it is involved in metastasis and the development of resistance. However, given that the TME is an intricate system of immune and stromal cells interacting with cancer cells, new immune-based therapies are being developed to target the TME of HCC. Therefore, understanding the complexity of the TME in HCC will provide new possibilities to design novel and more effective immunotherapeutics and combinatorial therapies to overcome resistance to treatment. In this review, we describe the role of inflammation during the development and progression of HCC by focusing on TME. We also describe the most recent therapeutic advances for HCC and possible combinatorial treatment options.

14 April 2023 in Science Advances
Verified
Journal Article
Open access
IWIsabel Weinhäuser
Isabel Weinhäuser
DPDiego A Pereira-Martins
Diego A Pereira-Martins
LALuciana Yamamoto de Almeida
Luciana Yamamoto de Almeida
JHJacobien R. Hilberink
Jacobien R. Hilberink
DSDouglas Silveira
Douglas Silveira
JSJan Jacob Schuringa
Jan Jacob Schuringa
It is increasingly becoming clear that cancers are a symbiosis of diverse cell types and tumor clones. Combined single-cell RNA sequencing, flow cytometry, and immunohistochemistry studies of the innate immune compartment in the bone marrow of patients with acute myeloid leukemia (AML) reveal a shift toward a tumor-supportive M2-polarized macrophage landscape with an altered transcriptional program, with enhanced fatty acid oxidation and NAD + generation. Functionally, these AML-associated macrophages display decreased phagocytic activity and intra–bone marrow coinjection of M2 macrophages together with leukemic blasts strongly enhances in vivo transformation potential. A 2-day in vitro exposure to M2 macrophages results in the accumulation of CALR low leukemic blast cells, which are now protected against phagocytosis. Moreover, M2-exposed “trained” leukemic blasts display increased mitochondrial metabolism, in part mediated via mitochondrial transfer. Our study provides insight into the mechanisms by which the immune landscape contributes to aggressive leukemia development and provides alternatives for targeting strategies aimed at the tumor microenvironment.

27 October 2020 in Cancers
Verified
Journal Article
Open access
PDF file
IWIsabel Weinhäuser
Isabel Weinhäuser
DPDiego A Pereira-Martins
Diego A Pereira-Martins
César Alexander Ortiz RojasCésar Alexander Ortiz Rojas
César Alexander Ortiz Rojas
DSDouglas Silveira
Douglas Silveira
LSLuíse Araújo de Albuquerque Simões
Luíse Araújo de Albuquerque Simões
EREduardo Rego
Eduardo Rego
The SLIT-ROBO axis plays an important role in normal stem-cell biology, with possible repercussions on cancer stem cell emergence. Although the Promyelocytic Leukemia (PML) protein can regulate SLIT2 expression in the central nervous system, little is known about SLIT2 in acute promyelocytic leukemia. Hence, we aimed to investigate the levels of SLIT2 in acute promyelocytic leukemia (APL) and assess its biological activity in vitro and in vivo. Our analysis indicated that blasts with SLIT2high transcript levels were associated with cell cycle arrest, while SLIT2low APL blasts displayed a more stem-cell like phenotype. In a retrospective analysis using a cohort of patients treated with all-trans retinoic acid (ATRA) and anthracyclines, high SLIT2 expression was correlated with reduced leukocyte count (p = 0.024), and independently associated with improved overall survival (hazard ratio: 0.94; 95% confidence interval: 0.92–0.97; p < 0.001). Functionally, SLIT2-knockdown in primary APL blasts and cell lines led to increased cell proliferation and resistance to arsenic trioxide induced apoptosis. Finally, in vivo transplant of Slit2-silenced primary APL blasts promoted increased leukocyte count (p = 0.001) and decreased overall survival (p = 0.002) compared with the control. In summary, our data highlight the tumor suppressive function of SLIT2 in APL and its deteriorating effects on disease progression when downregulated.

13 November 2019 in Blood
Verified
Journal Article
Open access
JCJuan L Coelho-Silva
Juan L Coelho-Silva
TBThiago Mantello Bianco
Thiago Mantello Bianco
ASAntonio Bruno Alves Silva
Antonio Bruno Alves Silva
DPDiego A Pereira-Martins
Diego A Pereira-Martins
NFNatasha Peixoto Fonseca
Natasha Peixoto Fonseca
FTFabiola Traina
Fabiola Traina
Background: Preclinical rationale of metformin treatment for myeloproliferative neoplasms (MPN) has recently been demonstrated (Cell Death Dis. 2018;9(3):311). Current MPN treatment options are mainly directed to symptoms and have not greatly improve clinical outcomes. It is a consensus that potential curative approaches should affects MPN stem cell function. Aims: To interrogate the metformin action in MPN stem cell function according to frequency and ex vivo differentiation capacity, as well as to underlying molecular mechanisms related to the treatment. Material and Methods: For induction of PV phenotype, 5×106 total bone marrow cells from Jak2V617F conditional mice (Jak2WT/V617F-CD45.2) were transplanted into lethally irradiated) Pep/boy mice (CD45.1-700cGy X-Ray). After 4 weeks, peripheral blood chimerism was evaluated by CD45.1 and CD45.2 markers (Becton-Dickinson) by flow cytrometry and mice were randomized for treatment by intraperitoneal injection of vehicle (PBS, n=6) or metformin (125 mg/kg/day, n=4) for 6 weeks according to chimerism and body weight. Erythroid progenitors (CD71 and Ter119) were evaluated in bone marrow (BM) and spleen. Hematopoietic stem and progenitor cells (LSK: Lin-Sca-1+C-KitHi/long-term HSC[LT-HSC]:LSKCD48-CD150+/ short-term HSC [ST-HSC]:LSKCD48+CD150+/multipotent progenitor [MPP]: LSKCD48+CD150-), myeloid progenitors (LK:Lin-Sca-1+C-KitHi/myelo-erythroid progenitor [MEP]: LKCD34-CD16/32-/common myeloid progenitors [CMP]: LKCD34+CD16/32-/granulocytic progenitors [GMP]: LKCD34+CD16/32+) were evaluated in BM by flow cytometry. BM stroma was evaluated according to frequencies of macrophages (F4/80+CD11b+), inflammatory macrophages (M1) (F4/80+CD11b+CD11c+), arterioles (Cd45/Ter119-CD31+Sca-1+), osteoblasts (Cd45/Ter119-CD51+Sca-1-) and mesenchymal stem cell (Cd45/Ter119-CD51+Sca-1+). BM c-Kit cells were enriched using AutoMacs separator with anti-CD117 magnetics beads (Miltenyi) and used for RNA extraction and PCR array for cell cycle and apoptosis (PAMM-020Z and PAMM-012Z, respectively-Qiagen). Genes with fold-change ≥2 in both directions were selected. All experiments were approved by the Animal Ethics Committee. For comparisons, unpaired T-test or Mann-Whitney test were used as appropriated. All P-values were two-sided with a significance level of 0.05. Results: At randomization, mice of both groups were similar according PB chimerism, body weight and blood counts (all P>0.05). After 6 weeks of metformin treatment mice had no evidence of hematological toxicity or weight loss. Metformin treated mice presented lower platelets counts in PB (mean for vehicle vs. metformin: 4370×103/uL vs. 3451×103/uL; P=0.04) and reduction of splenomegaly (P=0.02). Metformin reduced CD45.2 chimerism (92.7% vs. 88.9%; P=0.03), and showed a trend in reducing pro-erythroblasts (0.91% vs. 0.53%; P=0.06) and early erythroid progenitors (37.4% vs. 32.4%; P=0.11), while increased late erythroid progenitors (16.2% vs. 27.2%; P=0.008) in spleen. Metformin significantly increased ST-HSC frequency (0.06% vs. 0.29%; P=0.001) compared to vehicle. Conversely, bone marrow mononuclear cells from metformin treated mice showed decreased clonogenic capacity (2.5 colonies/1000 BMMC vs. 8.6 colonies/1000 BMMC; P=0.001). Competitive secondary transplant into lethally irradiated mice was performed and results will be show at meeting. Metformin treatment did not modulate the frequency of erythroid progenitors, LT-HSC, MPP, MEP, GMP and CMP in BM nor of the stromal cells evaluated. In c-Kit enriched cells, PCR-array identified 31 downregulated and 64 upregulated genes by metformin treatment. Metformin reduced expression of anti-apoptotic genes (Bcl2 [Fold-change: 0.33] and Xiap [0.48]), cell cycle regulators (Cdkn2a [0.21], Ccnd1 [0.27], Ccn1a [0.42]), while increased expression of TP53 family members (Trp63 [4.1] and Trp53 [2.1]), pro-apoptotic (Bid [2.5] and Bcl10 [1.9]) and cellular-stress response genes (Atm [66.9] and Cdkn2a [3.1]). Conclusions: In a conditional Jak2V617F-induced MPN murine model, daily treatment with metformin reduced tumor burden, extramedullary hematopoiesis, and clonogenic capacity of HSPC by acting on molecular processes related to maintenance and proliferation of MPN stem cell.

24 June 2024 in Blood Cancer Journal
Verified
Journal Article
Open access
PDF file
MSMaria L. Salustiano-Bandeira
Maria L. Salustiano-Bandeira
AMAmanda Moreira-Aguiar
Amanda Moreira-Aguiar
DPDiego A Pereira-Martins
Diego A Pereira-Martins
JCJuan L. Coelho-Silva
Juan L. Coelho-Silva
IWIsabel Weinhäuser
Isabel Weinhäuser
ALAntonio R Lucena-Araujo
Antonio R Lucena-Araujo

31 December 2022 in Cancers
Verified
Journal Article
Open access
PDF file
César Alexander Ortiz RojasCésar Alexander Ortiz Rojas
César Alexander Ortiz Rojas
ANAbel Costa Neto
Abel Costa Neto
DPDiego A Pereira-Martins
Diego A Pereira-Martins
DLDuy Minh Le
Duy Minh Le
DSDominique Sternadt
Dominique Sternadt
EREduardo Rego
Eduardo Rego
Several laboratory and clinical variables have been reported to be associated with the outcome of intensive chemotherapy for acute myeloid leukemia (AML), but only a few have been tested in the context of hematopoietic stem cell transplant (HSCT). This study aimed to identify genes whose expression of AML at diagnosis were associated with survival after HSCT. For this purpose, three publicly available adult AML cohorts (TCGA, BeatAML, and HOVON), whose patients were treated with intensive chemotherapy and then subjected to allogeneic or autologous HSCT, were included in this study. After whole transcriptome analysis, we identified ME1 as the only gene whose high expression was associated with shorter survival in patients subjected to HSCT. In addition, the inclusion of ME1 expression was able to improve the European LeukemiaNet risk stratification. Pathways related to lipid biosynthesis, mainly fatty acids, and cholesterol were positively correlated with ME1 expression. Furthermore, ME1 expression was associated with an M2 macrophage-enriched microenvironment, mature AML blasts hierarchy, and oxidative phosphorylation metabolism. Therefore, ME1 expression can be used as biomarker of poor response to HSCT in AML.